---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-24-000045"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:05:07.677759+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M

## Summary
- Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).
- Net loss $13.7M ($0.36 per share) versus $15.9M ($0.42) in Q1 2023; Adjusted EBITDA loss $8M vs $11.2M.
- Gross margin 75% (vs 73% YoY); FY 2024 revenue guidance reaffirmed $81M-$84M; operating expenses guidance tightened to $127M-$129M.
- Cash and equivalents $120.4M; clinical milestones: first AeriSeal CONVERT II patient and first Japanese Zephyr post-approval patient.

## SEC filing metadata
- accession: 0001127537-24-000045
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000045/0001127537-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000045/lung-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-24-000045
- JSON: https://secwatch.observer/filing/0001127537-24-000045.json
- Plain text: https://secwatch.observer/filing/0001127537-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.